7 / 31
PACIFIC Regimen
Mechanism of Action
Antigens
Chemotherapy
Radiation
Antigen-presenting
Cell
Antigens
Active
T cell
PD-L1
PD-1
Inactive
T cells
Tumor
Durvalumab reverses immune
suppression and leads to a systemic
antitumor response
DURVALUMAB
CHEMORADIATION
Chemoradiation induces
tumor antigen release and
an adaptive immune response
PD-L1 overexpression
leads to immune
cell evasion
Durvalumab